BIOGRAPHICAL SKETCH

Academic & Professional Background

• M.D. (Medicine) 1972 - Napur Medical College, India
• Residency (Internal Medicine) 1976-1978 - The Chicago Medical School, North Chicago, IL
• Fellowship (Pulmonary Medicine) 1978-1980 - University of Chicago, Chicago, IL

Current Research Interests

• Respiratory Infections
• COPD
• Pulmonary Function Variability in Ethnicity
• Bronchodilator Drugs

Selected Publications

Long Term Effectiveness of Nasal CPAP in Mild Sleep Apnea Compared to Conservative Measures. R.H. Shashikumar, MD, Ashok Fulambarker, MD. 2002. Chest 2002; 122-4, 130S.

Analysis of Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) Treated With and Without Antibiotics: A Retrospective Study. Shazli Manzoor, MD, Ashok Fulambarker, MD. 2002. Chest 2002; 122-4, 46S.

GJ Gorse, TZ O’Connor, SL Young, SF Bradley, KL Nichol, JH Strickland, DM Paulson, RA Foster, A Fulambarker, JW Shigeoka, JE Stasek, K Boardman, PM Mendelman, P. Peduzzi. Efficacy of Live, Cold-Adapted, Influenze Virus Vaccine, Trivalent (CAIV-T) and Inactivated InfluenzaVirus Vaccine (TVV) in Adults with Chronic Obstructive Pulmonary Disease (COPD): A VA Cooperative Study. In press, Vaccine, 2003.

GJ Gorse, TZ O’Connor, FK Newman, MD Mandava, PM Mendelman, P Peduzzi and VA Cooperative Study Group *AM Fulambarker. Immunogenicity of Influenza Virus and Immune Correlates of Protection from Natural Infection in Adults with Chronic Obstructive Pulmonary Disease (COPD): A VA Cooperative Study. Abstract of the IDSA 39th Annual Meeting. 363; 101, 2001.

GJ Gorse, TZ O’Connor, SL Young, SF Bradley, KL Nichol, JH Strickland, DM Paulson, RA Foster, A Fulambarker, JW Shigeoka, JE Stasek, K Boardman, PM Mendelman, P. Peduzzi. Efficacy of Live, Cold-Adapted, Influenze Virus Vaccine, Trivalent (CAIV-T) and Inactivated InfluenzaVirus Vaccine (TVV) in Adults with Chronic Obstructive Pulmonary Disease (COPD): A VA Cooperative Study. Abstracts of the IDSA 39th Annual Meeting. 364; 101, 2001.

Fulambarker A , Copur AS, Ferguson D, Jere S. Prediction Equations for Pulmonary Function in Asian Indians Living in United States. Am J Respir Crit Care Med. 159,3, A835: 1999.

Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA and VA Cooperative Study Group * Fulambarker A M. Effects of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary disease. N Engl J Med 1999; 340: 1941-7.

Fulambarker A M, Copur AS, Chandok S. Energy Expenditure in patients with Pressure sores. Am J Respir Crit Care Med. 157, 3, 838; 1998.

Fulambarker A M, Ferguson, D. Pulmonary Function in Asian Indians in the United States. A comparison of Predicted Equations. European Respiratory Journal 9:23, 469, 1997.

Tzelepis G, Komanapolli S, Tyler D, Vega D, and Fulambarker A . Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J 9:100-103; 1996.

Fulambarker A , Lund D, Chandok S, Tyler D. Effect of Pulmonary Rehabilitation Program on Hospital days of COPD patients. Chest 108-114; 1995.

Tzelepis G, Vega D, Cohen ME, Fulambarker A . Pressure-flow specificity of inspiratory muscle training. J Appl Physiol 77:795-801; 1994.

Gilden JL, Fulambarker A , Vega D and Singh SP. Respiratory abnormalities in insulin-dependent and non-insulin dependent diabetics with autonomic and peripheral neuropathy. Clinical Autonomic Research 3:209, 1993.

Komanapalli S, Fulambarker A , Tyler D, Vega D, Patel J. Tzelepis G. Effects of glycopyrrolate and metaproterenol alone and in combination in COPD. Am Rev Respir Dis. 147:316; 1993.

Patel KK, Patel J, Tyler D, Tzelepis G, Rosman J, Fulambarker A . Comparison of aerosolized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Am Rev Respir Dis. 147:316; 1993.

Tzelepis G, Vega D, Patel K. Fulambarker A . Pressure-flow specificity of the inspiratory muscle training. Am Rev Respir Dis. 145:A151; 1992.

Fulambarker A M, Gilden J, Tyler D, Vega D. Differences in the pulmonary function and respiratory muscle performance between insulin dependent and non-insulin dependent diabetes mellitus. Am Rev Respir Dis. 143:A533; 1991.

Tzelepis G, Vega D, Fulambarker A , Rosman J, Bruyntjens C, McCool FD. Lung volume specificity of the inspiratory muscle training. Am Rev. Respir Dis 143:368; 1991.

Fulambarker A M, Rackow EC, Weil MH. Acute respiratory failure in chronic obstructive pulmonary disease, pp. 731-735. In Kassirer JP: Current Therapy in Internal Medicine. BC Decker Inc., Philadelphia, Pennsylvania, 3rd Edition, 1991.

Gilden JL, Singh SP, Fulambarker A , Vega D, Douglas FL. Role of B-endorphines in glucose counter-regulation during exercise in insulin dependent diabetes mellitus. Exp. Clin. Endocrinol. 10:209-218; 1991.

Fulambarker A M, Gilden J, Vega D, Tzelepis G. Pulmonary function and respiratory muscle strength in insulin dependent diabetes mellitus. Chest 98:395; 1990.

Fulambarker A M, Rackow EC, Weil MH. Acute respiratory failure in chronic obstructive pulmonary disease, pp. 342-345. In RM Cherniack: Current Therapy of Respiratory Disease. BC Decker Inc., Philadelphia, 3rd Ed., 1989.

Ivanovich M, Fulambarker A . Why did the jogger become short of breath? Diagnosis 10:13-200, 1988.

Almenoff P, Goldberg N, Rubinstein L, Vega D, Fulambarker A . The use of breath holding time to predict airflow obstruction. Am Rev Respir Dis. 137:449; 1988.

O’Gara J, Bowen P, Petersen J, Fulambarker A , Bourlier P. Respiratory muscle strength and nutritional status of the supplemented emphysema patients. Nutrition 6:447, 1987.

Sainani GS, Fulambarker A M. Study of bacterial pneumonias – evaluation of lung biopsy. J Assoc Phys India, 23: 503-506; 1975.

Sainani GS, Fulambarker A M, Khurana KB. A double blind clinical trial of fenfluramine in the treatment of obesity. Brit J Clin Prat, 27: 136-138; 1973.

Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A . Comparison of nebulized glycopyrrolate and metaproternol in chronic obstructive pulmonary disease. Eur Respir J 9:100-103, 1996.

Projects Completed or Active (Selected)

• Analysis of patients with acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) treated with and without antibiotics: A Retrospective Study. Shazli Manzoor, MD, Ashok Fulambarker, MD. 2002.
• Long term effectiveness of Nasal CPAP in Mild Sleep Apnea Compared to Conservative Measures. R.H. Shashikumar, MD, Ashok Fulambarker, MD. 2002.
• Does smoking cessation affect the level of IL-8 in induced sputum and in serum of patients with COPD? Ahmad Raslan, MD, Isabel Crisostomo, MD, Ashok Fulambarker, MD. 2002.
• Outcome of COPD patients on mechanical ventilator with and without systemic corticosteroids. Vineet Sood, MD, Ashok Fulambarker, MD. 2002.
• Randomized double-blind, placebo controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. VA Cooperative Study in collaboration with Boehringer – Ingelheim. Ashok Fulambarker, MD. 2001.
• A Phase 2 Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury. Frank Maldonado, MD. 2002.
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the long term effects of salmeterol/fluticasone propionate (Seretide/Viani/Advair) 50/500 mg bd, salmeterol 50 mg bd and fluticasone propionate 500mg bd, all delivered via the Discus/ Accuhaler inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. Glaxo Study. Ashok Fulambarker, MD. 2001.
• Multicenter, double-blind, randomized, placebo-controlled study comparing the effects of three doses of INS365 to placebo administered via the Pari LC Star Nebulizer on symptoms and respiratory health status in subjects with mild to moderate Chronic Bronchitis. Inspire Pharmaceutical. Ashok Fulambarker, MD. 2001.
• A Randomized double blind, Phase III, comparative study of Cidecin (Daptomycin) to Rocephin (Ceftriaxone) in the treatment of Moderate to Severe Community Acquired Acute Bacterial Pneumonia due to S. Pneumoniae. Cubist Pharmaceuticals. Ashok Fulambarker, MD. 2000-2001.
• Randomized, double-blind, double-dummy, multicenter, parallel group study to compare the efficacy, safety and tolerability of Intravenous Gemifloxacin followed by Oral Gemifloxacin versus Intravenous Ceftriaxone followed by Oral Levofloxacin in the treatment of Nosocomial Pneumonia (NP) in adults at low risk for infection with Pseudomonas Aeroginosa. SmithKline Beecham. Ashok Fulambarker, MD. 2001.
• Prevent Respiratory Exacerbations in COPD by Immune Stimulation (PRECIS). A Cooperative Trial conducted by the department of Medicine at the Veterans Affairs Medical Center, Minneapolis, Minnesota supported by OM Pharma, Geneva, Switzerland. Ashok Fulambarker, MD. Expected to resume 2002.
• A Randomized double-blind, double-dummy, multicenter, parallel group study to assess the efficacy and safety of Oral Gemifloxacin( Factive) 320 mg Once Daily for 5 days versus Oral Levofloxacin 500 mg Once Daily for 7 days for the treatment of Acute Exacerbations of Chronic Bronchitis. SmithKline Beecham. Ashok Fulambarker, MD. 2000.
• Prospective, randomized, double-blinded, multicenter comparison of the safety and efficacy of Oral Moxifloxacin 400 mg QD for 5 days vs. Azithromycin 250 mg QD for 5 days (500mg QD for the first day) For the treatment of Acute exacerbation of Chronic bronchitis or Oral Moxifloxacin 400 mg QD for 10 days vs. Amoxicillin/ Clavulanate 875 mg BID for 10 days. For the treatment of Acute Maxillary Sinusitis Infection” sponsored by Bayer. Ashok Fulambarker, MD. 1999.
• Dynamic changes of Upper Airway during exercise in-patients with Obstructive Sleep Apnea. A. Sarrigiannidis, MD, Ashok Fulambarker, MD. 1999.
• Analysis of reduced pulmonary function in healthy Non-Smoking Asian Indians. Ashok Fulambarker, M.D. Completed 2001.
• Compare safety & efficacy of Cefditoren Pivoxil & Amoxicillin in treatment of Community Acquired Pneumonia. TAP Pharma. Ashok Fulambarker, MD. 1999.
• Linezolid in the treatment of patients with Nosocomial Pneumonia. Pharmacia and Upjohn. Frank Maldonado, MD, Raul Gazmuri, MD. 2000.
• A Randomized, controlled, blinded, multicenter trial to assess the efficacy of protection from the Natural Influenza Virus Infection of the Influenza Virus Vaccine, Trivalent, Types A and B, Live, Cold-adapted (CAIV-T) and Inactivated Influenza Virus Vaccine in Patients with COPD. CSP#48. Ashok Fulambarker, MD. Completed 2000.

Research Funding Sources

• Genentech, Inc.
• VA Cooperative Studies
• Wyeth Laboratories

Research Methods Employed

• Randomized Double-Blind Clinical Trials

Honors

• 1992 - Teacher of the Year Award, The Chicago Medical School, North Chicago, IL
• 1997 - Course Director, Symposium of Pulmonary Medicine Update, The Chicago Medical School, North Chicago, IL